Logo image
Back
Morbidity and mortality in sarcoidosis
Journal article   Open access

Morbidity and mortality in sarcoidosis

Alicia K Gerke
Current opinion in pulmonary medicine, Vol.20(5), pp.472-478
09/2014
DOI: 10.1097/MCP.0000000000000080
PMCID: PMC4326053
PMID: 25029298
url
https://doi.org/10.1097/MCP.0000000000000080View
Published (Version of record) Open Access

Abstract

Chronic sarcoidosis is a complex disease with numerous comorbid conditions and can be fatal in some cases. Recognizing causes of morbidity and mortality is important to effectively select treatments, manage symptoms and improve outcomes. The purpose of this review is to examine emerging knowledge on morbidity and mortality in sarcoidosis. Approximately 1-5% of patients with sarcoidosis die from complications of sarcoidosis. Recent population studies indicate that mortality may be increasing over the past decade. The reasons behind these trends are unclear, but could include increasing incidence, detection rates, severity of disease or age of the population. Morbidity of sarcoidosis is reflected by a trend of increased hospitalizations over recent years and increased use of healthcare resources. Morbidity can be caused by organ damage from granulomatous inflammation, treatment complications and psychosocial effects of the disease. Recent studies are focused on morbidity related to cardiopulmonary complications, bone health and ageing within the sarcoidosis population. Last, sarcoidosis is associated with autoimmune diseases, pulmonary embolism and malignancy; however, the underlying mechanisms linking diseases continue to be debated. Morbidity in sarcoidosis is significant and multifactorial. Mortality is infrequent, but may be increasing over the years.
 Sarcoidosis - epidemiology Hospitalization - trends Humans Aging Fatigue - etiology Pain - etiology Morbidity Incidence

Details

Metrics

16 Record Views
93 Times Cited - Web of Science
Logo image